Acalabrutinib (Calquence) and zanubrutinib (Brukinsa) have been found to be much better tolerated than than ibrutinib, with lower adverse event and side effect profiles. However which BTKi drug we find to be most tolerable is highly individual and there's no way of knowing ahead of taking it.
While we are highly unlikely to see a head to head comparison of acalabrutinib and zanubrutinib, this real world study may provide some guidance to those fortunate enough to be faced with a choice.
The objective of this study was to evaluate real-world switching and sequencing to next line of therapy in patients (pts) initiating BTKis as first-line (1L) or second-line (2L) CLL/SLL treatment.
Conclusions: Zanu pts had significantly lower switching rate within 90 days and lower proportion of pts receiving next line of therapy at 180 days when compared with acala and ibru in 1L and 2L. Longer follow-up and larger zanu sample size are required for a comprehensive assessment of treatment outcomes associated with use of BTKis in CLL/SLL.
ascopubs.org/doi/10.1200/JC...
Note also the author disclosures with regard to potential conflicts of interest
coi.asco.org/Report/ViewAbs...
Neil
